Jim Gaffigan isn't ashamed to admit he jumped on the weight-loss medication bandwagon. In a new interview, the comedian ...

Hims & Hers introduced a new tracker to monitor shortages of GLP-1 weight loss and diabetes drugs, responding to the FDA's decision to end the compounded versions, Yahoo Finance reported Nov. 13.

A phase 3 trial found that Eli Lilly's tirzepatide significantly reduced the risk of progression to Type 2 diabetes in prediabetic adults over a three-year period. Nearly 99% of individuals treated ...

Three stocks that have not only been around for a century but have also been paying dividends for that long are Coca-Cola ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

US Food and Drug Administration (FDA) regulations allow human drug compounding — in which licensed pharmacists or physicians ...

Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...

Whether these departments get the money will be decided later, but the Scene listened in on requests from the Department of ...

Lou Scofield weighed her heaviest in 2023 at 17.5st and wore a size 20 clothes due to being perimenopausal and comfort eating ...

Semaglutide and a similar GLP-1 drug, tirzepatide (Mounjaro/Zepbound), had been on the FDA’s shortages list since 2022, as the popularity of the medicines, known as GLP-1 receptor agonists, soared.